Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.56 |
| ▸ | MGLL | Q99685 | 3/20 | 0.56 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.49 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.49 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.49 |
| ▸ | CCKAR | P32238 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764962 | 0.91 | FAAH (0.55) | FAAHMGLLSLC5A1CHRNA7SCN9A | |
| SCHEMBL1765509 | 0.89 | CCKAR (0.60) | FAAHMGLLLMNATP53CHRNA7 | |
| SCHEMBL1764934 | 0.89 | LMNA (0.59) | FAAHMGLLLMNATP53CHRNA7 | |
| SCHEMBL1765033 | 0.87 | FAAH (0.58) | FAAHMGLLLMNATP53CHRNA7 | |
| SCHEMBL2194152 | 0.87 | FAAH (0.54) | FAAHMGLLSLC5A1LMNATP53 | |
| SCHEMBL1110689 | 0.87 | PPP1CA (0.64) | FAAHSLC5A1SLC16A3SLC16A1MCTS1 | |
| SCHEMBL1764923 | 0.86 | FAAH (0.56) | FAAHMGLLLMNATP53CHRNA7 | |
| SCHEMBL1764964 | 0.86 | FAAH (0.53) | FAAHMGLLLMNATP53CHRNA7 | |
| SCHEMBL1110679 | 0.86 | SLC5A1 (0.51) | FAAHMGLLSLC5A1SLC16A3SLC16A1 | |
| SCHEMBL2193229 | 0.85 | CA9 (0.65) | FAAHMGLLLMNATP53CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2278965-B1 | SUBSTITUTED PYRAZOLAMIDES AND THE USE THEREOF | AICURIS GMBH & CO KG (DE) | 2013-11-13 | — | — | EP | disclosed |
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8314089-B2 | Substituted pyrazolamides and their use | AICURIS GMBH & CO. KG (DE) | 2012-11-20 | — | — | US | disclosed |
| US-8314089-B2 | Substituted pyrazolamides and their use | AICURIS GMBH & CO. KG (DE) | 2012-11-20 | — | — | US | disclosed |
| US-20110172207-A1 | SUBSTITUTED PYRAZOLAMIDES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172207-A1 | SUBSTITUTED PYRAZOLAMIDES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172207-A1 | SUBSTITUTED PYRAZOLAMIDES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| WO-2009115213-A1 | (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009115252-A2 | SUBSTITUTED PYRAZOLAMIDES AND THE USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | TPMT, PAICS, THPO | FAAH 4725/4885MGLL 4676/4885SLC5A1 2409/4885 |
| US-20110172207-A1 | SUBSTITUTED PYRAZOLAMIDES AND THEIR USE | CACNA1A, P2RX4, KCNH1 | FAAH 1131/4885MGLL 4690/4885SLC5A1 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.